The Catalyst

Most Recent Posts

12.06.13 | By Kaelan Hollon

It’s a basic tenant of our industry: the well-being of patients is one of the most important pillars of the biopharmaceutical industry. Whether in the creation of new medications or updating information about current medicine, our industry strives to educate patients safely and transparently on the status of treatments that could change their lives.

12.06.13

Birthdays provide a great opportunity to look back and reflect on accomplishments made along the way. On December 8, 2003, the Medicare Prescription Drug, Improvement, and Modernization Act, which created Medicare Part D, was signed into law. Since its enactment 10 years ago, the program has racked up an impressive track record.

12.05.13

If you follow PhRMA and especially the Catalyst, you’ll notice we spend a lot of time focusing on how innovative medicines can be a great, transformative technology. A great example includes this morning’s NPR Morning Edition, reporting on new medicines to treat Hepatitis C, soon to be approved by the FDA. 

12.05.13

Biopharmaceutical research companies have already conducted more than 3,400 clinical trials of new medicines in Alabama since 1999.  And Governor Robert Bentley made clear yesterday his desire to see the valuable partnership between the biopharmaceutical sector and his state’s research institutions continue well into the future.

12.04.13 | By Dr. Bill Chin

Earlier this year, PhRMA member companies, along with member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA), announced new 

12.02.13 | By Mark Grayson

Fake medicines put patients and the public at risk. In the U.S. almost all fake medicines enter the drug supply through purchases over the internet. This is a pervasive problem all around the world.

11.22.13 | By Kaelan Hollon

With Thanksgiving right around the corner, it’s a good opportunity to reflect on what we’re thankful for and the progress we’ve made this year. For the biopharmaceutical research companies discovering new medicines, we're proud of our advancements that have helped develop new treatments and ensured the health and safety of our patients.

11.19.13

Prostate cancer is the second-most common form of cancer affecting men. In 2013, it is estimated that nearly 240,000 American men will be diagnosed with the disease and 29,000 will die from it.

11.15.13 | By Salvatore Alesci

The newly released American Heart Association (AHA) and American College of Cardiology (ACC) Guidelines on the Treatment of Blood Cholesterol and Lifestyle Management to Reduce Atherosclerotic Cardiovascular Risk in Adults have received a great deal of attention over the last couple days and are certain to stimulate further discussion as p

11.15.13

Guest Post from Erin Mullen, PhRMA Associate VP and Director of Rx Response

11.14.13 | By Dr. Bill Chin

The healthcare community is at an important juncture; we must work together to ensure that policies and regulations align to help us meet the unique challenges and full potential of personalized medicine. Science and technology drive what we can achieve, but they also evolve over time.

11.14.13

In science – and especially medicine -- there are celebrated men and women whose life work has changed the world.  Doctors Salk and Sabine and their polio vaccines come quickly to mind.  Because of their work, people around the world need never fear the scourge of polio.

11.13.13

With nearly 1,700 care locations throughout the country and serving more than eight million Veterans, service members and military families each year, the Veterans Health Administration, part of the U.S. Department of Veterans Affairs (VA), is the largest integrated health care system in the country.

11.13.13
The report, "Research in Your Backyard:  Pharmaceutical Clinical Trials in Massachusetts," shows widespread clinical research underway throughout the state, including Worcester where we released the report yesterday with the
11.12.13 | By John Castellani

Over the last few weeks we have devoted a fair bit of time and energy on Alzheimer’s disease. Why? It is one of the most complex diseases we face, it currently afflicts more than 5 million people in the U.S. and its current trajectory is worrisome to say the least.

Pages